CD274 and diffuse large B-cell lymphoma: At 3-month follow-up (n = 7 evaluable), treatment responses stratified as five CR (71.4%), one PR (14.3%), and two progressive disease (28.6%), demonstrating enhanced therapeutic synergy between CAR-T and PD-(L)1 blockade in R/R DLBCL.